StockNews.com lowered shares of Sangamo Therapeutics (NASDAQ:SGMO – Free Report) from a hold rating to a sell rating in a research note released on Tuesday. Other analysts also recently issued reports about the company. HC Wainwright lowered their price target on Sangamo Therapeutics from $15.00 to $5.00 in a research report on Monday, May 1st. […]
/PRNewswire/ The "CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report, By Target Antigen, By Indication, By Region, Segment Forecast,.
StockNews.com lowered shares of Sangamo Therapeutics (NASDAQ:SGMO – Free Report) from a hold rating to a sell rating in a report released on Tuesday. Other analysts have also recently issued reports about the company. Bank of America cut Sangamo Therapeutics from a neutral rating to an underperform rating and lowered their target price for the […]
Sangamo Therapeutics (NASDAQ:SGMO – Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Tuesday. Other analysts have also recently issued research reports about the stock. Truist Financial lowered their target price on shares of Sangamo Therapeutics from $16.00 to $8.00 in a […]
Sangamo Therapeutics, Inc : Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.